5/7/2013

An analysis of nearly 9,000 clinical trials of cancer therapies conducted between 2007 and 2010 found the trials tend to be smaller and less robust than trials for therapies in other disease areas. The Duke University analysis was part of the FDA's Clinical Trials Transformation Initiative to improve the quality and efficiency of clinical trials. Oncology trials tended to be small, early-stage and nonrandomized, researchers reported in JAMA Internal Medicine.

Full Story:
PharmaTimes (U.K.)

Related Summaries